At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 14, 2026 at 05:15 ET
Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug showed rapid, durable, dose-dependent reductions in serum tryptase (indicating mast cell depletion) and was well-tolerated at all doses with no dose-limiting toxicities or related serious adverse events. This validates a novel mechanism (neutralizing soluble SCF to selectively inhibit KIT signaling in mast cells) and supports advancing into Phase 1b proof-of-concept studies in asthma, allergic rhinitis, and food allergy.
- CDX-622 induced rapid, profound, dose-dependent, and durable reductions in serum tryptase, indicating tissue mast cell depletion.
- No dose-limiting toxicities or related serious adverse events; most common adverse event was Grade 1 headache.
- No changes in hair/skin pigmentation or meaningful impact on hematologic parameters, addressing a key safety concern for KIT-targeting therapies.
- CDX-622 exhibited monoclonal antibody-like pharmacokinetics with extended half-life and good subcutaneous bioavailability.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access